Evaluation of Fecal Calprotectin before and after Anti-TNF Therapy in Patients with Inflammatory Bowel Syndrome

Naser Ebrahimi-Daryani, Elham Pishgar, Forough Alborzi Ivanaki, Faezeh Almasi



Ulcerative colitis (UC) and Crohn’s disease are chronic relapsing disorders in which their clinical activity and treatment response are evaluated by various indices. The response rate is unpredictable, and for its evaluation, we use invasive procedures like colonoscopy and blood samples to address this issue. The current study was designed to evaluate the accuracy of fecal calprotectin before and after treatment with anti-tumor necrosis factor (TNF) in patients with inflammatory bowel disease (IBD).

Materials and Methods:

46 patients with IBD who were a candidate for anti-TNF therapies were evaluated and the correlation between fecal calprotectin and disease activity before and after 5 months of treatment was studied.


Fecal calprotectin and disease activity after treatment with anti-TNF correlate, but before treatment, there was no correlation in the patients with UC.


Fecal calprotectin not on its own but alongside other tests could be used for follow-up treatment.


Inflammatory Bowel Diseases, Anti-TNF, Fecal calprotectin.

Full Text:


Copyright (c) 2022 GOVARESH

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.